Arcutis Biotherapeutics (ARQT) Preferred Stock Liabilities (2019)
Arcutis Biotherapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $166.5 million for Q4 2019.
- For Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $166.5 million; the TTM value through Dec 2019 reached $166.5 million, changed N/A, while the annual FY2019 figure was $166.5 million, N/A changed from the prior year.
- Preferred Stock Liabilities for Q4 2019 was $166.5 million at Arcutis Biotherapeutics.
- Over five years, Preferred Stock Liabilities peaked at $166.5 million in Q4 2019 and troughed at $166.5 million in Q4 2019.